Completed
PHASE3
INTERVENTIONAL
NCT03730662
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC.
Name:
Insulin Glargine
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
TimeFrame:
Baseline, Week 52
Description:
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Pooled Country + Baseline sodium-glucose co-transporter-2 inhibitor (SGLT-2i) use Flag (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Trial Information
NCT ID
NCT03730662
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025